RxSight (RXST) Cost of Revenue (2020 - 2026)

RxSight's Cost of Revenue history runs 7 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• Quarterly Cost of Revenue fell 22.69% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.3 million (down 29.77% YoY) and the FY2025 annual result came in at $31.5 million, down 23.21% from the prior year.
• Cost of Revenue was $7.4 million for Q1 2026 at RxSight, up from $7.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $11.4 million in Q4 2024 and bottomed at $5.2 million in Q1 2022.
• A 5-year average of $8.4 million and a median of $8.5 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 119.07% — and 2025, when it plunged 39.44%.
• RxSight's Cost of Revenue stood at $8.7 million in 2022, then climbed by 26.08% to $10.9 million in 2023, then advanced by 4.58% to $11.4 million in 2024, then tumbled by 35.72% to $7.3 million in 2025, then gained by 0.68% to $7.4 million in 2026.
• Business Quant data shows RXST's Cost of Revenue at $7.4 million in Q1 2026, $7.3 million in Q4 2025, and $6.1 million in Q3 2025.